Stay updated on Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page.

Latest updates to the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check21 days agoChange DetectedThe page’s footer revision label has been updated from **v3.5.2** to **v3.5.3**, indicating a minor site release without changing the displayed study record information.SummaryDifference0.0%

- Check28 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check35 days agoChange DetectedAdded new study details for Nadunolimab in combination with gemcitabine and carboplatin (TRIFOUR), including Phase Ib/II design and updated dates. Removed the prior TRIFOUR entry and related outdated notes.SummaryDifference0.4%

- Check57 days agoChange Detected- Revision: v3.5.0 added in the header; the previous version v3.4.3 was removed from the display.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page revision updated from v3.4.2 to v3.4.3. No trial details or study data appear to be changed.SummaryDifference0.0%

- Check92 days agoChange DetectedRevision: v3.4.2 was added and older notices, including the government funding lapse notice and Revision: v3.4.1, were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

Stay in the know with updates to Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nadunolimab Combo for Triple Negative Breast Cancer Clinical Trial page.